CIBC Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.78M | Buy |
|
|||||
|
2025
Q1 | $1.46M | Buy |
|
|||||
|
2024
Q4 | $1.21M | Buy |
|
|||||
|
2024
Q3 | $1.23M | Buy |
|
|||||
|
2024
Q2 | $1.03M | Buy |
|
|||||
|
2024
Q1 | $601K | Buy |
|
|||||
|
2023
Q4 | $768K | Sell |
|
|||||
|
2023
Q3 | $765K | Buy |
|
|||||
|
2023
Q2 | $797K | Buy |
|
|||||
|
2023
Q1 | $840K | Buy |
|
|||||
|
2022
Q4 | $976K | Sell |
|
|||||
|
2022
Q3 | $1.06M | Buy |
|
|||||
|
2022
Q2 | $772K | Sell |
|
|||||
|
2022
Q1 | $880K | Buy |
|
|||||
|
2021
Q4 | $909K | Buy |
|
|||||
|
2021
Q3 | $902K | Buy |
|
|||||
|
2021
Q2 | $738K | Buy |
|
|||||
|
2021
Q1 | $613K | Buy |
|
|||||
|
2020
Q4 | $543K | Hold |
|
|||||
|
2020
Q3 | $608K | Buy |
|
|||||
|
2020
Q2 | $604K | Hold |
|
|||||
|
2020
Q1 | $444K | Sell |
|
|||||
|
2019
Q4 | $550K | Buy |
|
|||||
|
2019
Q3 | $342K | Sell |
|
|||||
|
2019
Q2 | $328K | Hold |
|
|||||
|
2019
Q1 | $423K | Buy |
|
|||||
|
2018
Q4 | $289K | Sell |
|
|||||
|
2018
Q3 | $349K | Sell |
|
|||||
|
2018
Q2 | $403K | Buy |
|
|||||
|
2018
Q1 | $432K | Buy |
|
|||||
|
2017
Q4 | $393K | Hold |
|
|||||
|
2017
Q3 | $363K | Buy |
|
|||||
|
2017
Q2 | $221K | Buy |
|
|||||
|
2016
Q4 | – | Sell |
|
|||||
|
2016
Q3 | $303K | Buy |
|
|||||
|
2016
Q2 | $229K | Buy |
|
|||||
|
2016
Q1 | $256K | Buy |
|
|||||
|
2015
Q4 | $344K | Buy |
|
|||||
|
2015
Q3 | $255K | Buy |
|
|||||
|
2015
Q2 | $308K | Buy |
|
|||||
|
2015
Q1 | $235K | Buy |
|